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Objective: To evaluate the relationship between serum levels of the soluble 
Receptor for Advanced Glycation End-products (sRAGE) and mortality in frail and 
non-frail older adults. 
Methods: We studied 691 subjects (141 frail and 550 non-frail) with a median age of 
75 years from two population-based cohorts, the Toledo Study of Healthy Aging and 
the AMI study, who were enrolled to the FRAILOMIC initiative. Multivariate Cox 
proportional hazards regression and Kaplan-Meier survival analysis were used to 
assess the relationship between baseline sRAGE and mortality. 
Results: During 6 years of follow-up 101 participants died (50 frail and 51 non-frail). 
Frail individuals who died had significantly higher sRAGE levels than those who 
survived (median [IQR]: 1563 [1015-2248] vs 1184 [870-1657] pg/mL, P=0.006), 
whilst no differences were observed in the non-frail group (1262 [1056-1554] vs 1186 
[919-1551] pg/mL, P=0.19). Among frail individuals higher sRAGE levels were 
associated with an increased risk of death after adjustment for relevant covariates 
(HR=2.72 per unit increment in ln-sRAGE, 95%CI 1.48-4.99, P=0.001). In contrast, 
in non-frail individuals sRAGE showed no association with mortality. Survival curves 
demonstrated that among frail individuals the incidence of death was significantly 
higher in the top sRAGE quartile compared to the three lower quartiles (P=0.002). 
Area under the ROC curve analysis demonstrated that for frail individuals, inclusion 
of sRAGE in the hazard model increased its predictive accuracy by ~3%. 
Conclusions: sRAGE is an independent predictor of mortality among frail 
individuals. Determination of sRAGE in frail subjects could be useful for prognostic 




Frailty is an age-associated biological syndrome characterized by a decline in 
physical and mental reserves, a decrease in resistance to external stressors and an 
enhanced risk of disability, hospitalization and death [1, 2]. Although frailty is known 
to be a major cause of poorer survival in older adults, and despite the fact that 
identification of biomarkers associated with excess mortality in this condition could 
be of clinical prognostic value, these have not been extensively investigated.  
The Receptor for Advanced Glycation End-products (RAGE) is a transmembrane 
glycoprotein of the immunoglobulin superfamily. RAGE binds a variety of damage 
and stress-associated molecules, including advanced glycation-end products, high-
mobility group box 1 and S100 proteins. Upon activation, RAGE elicits pro-
inflammatory processes [3]. In addition to membrane-bound RAGE, there are two 
soluble RAGE (sRAGE) isoforms circulating in blood, both of which lack its 
membrane and cytoplasmic domains [4]. The predominant form of sRAGE is 
generated by proteolytic cleavage of membrane-bound RAGE [5, 6]. The second 
form, called esRAGE, results from alternative splicing of RAGE mRNA and accounts 
for <25% of total sRAGE [7]. Although the precise function of sRAGE in human 
biology remains unresolved [4], evidence suggests that its total circulating levels 
reflect increased RAGE activation [6], thus potentially making it a useful biomarker of 
underlying inflammatory pathologies [8]. 
Frailty is associated with a high prevalence of age-related comorbidities [1, 9]. 
However, these alone do not account for the higher mortality rates seen in people 
afflicted by this syndrome. Frailty has been also associated with chronic 
inflammatory mechanisms [10, 11], which could potentially affect its evolution. 
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Therefore, we surmised that elevated serum sRAGE could be a marker of poor 
survival in frail older adults. To address this hypothesis we investigated the 
relationship between sRAGE and mortality in a prospective study of European older 
adults living in the community.  
Methods 
Participants 
Participants in this study were men and women aged 65 and older from two well 
characterised population-based European cohorts, namely, Toledo Study of Healthy 
Ageing (TSHA) [12] and Approche Multidisciplinaire Intégrée (AMI) [13], who were 
enrolled in 2013 to the exploratory phase of FRAILOMIC, a European project 
investigating biomarkers of frailty [14] (for cohort details and selection of participants 
see Appendix 1, available at Age and Ageing online). 
The TSHA study protocol was approved by the Clinical Research Ethics Committee 
of the Complejo Hospitalario de Toledo (Spain) and the AMI study was approved by 
the Ethics Committee of the CHU (University Hospital) of Bordeaux (France). The 
research followed the principles embodied in the Declaration of Helsinki. 
Measurement of frailty 
Frailty was evaluated using Fried’s frailty phenotype [1], which includes five criteria, 
namely slow walking speed, weakness, weight loss, self-reported exhaustion, and 
low physical activity (for a detailed description of the frailty criteria see Appendix 1). 
In this study individuals meeting three or more criteria were classed as frail and 
those who met none, one or two criteria were classed as non-frail. 
Measurement of sRAGE 
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Serum levels of sRAGE were determined from fasting blood samples stored at -80°C 
using a commercially available sandwich ELISA which detects both, cleaved sRAGE 
and esRAGE (Quantikine Human RAGE Immunoassay, R&D Systems, Abingdon, 
UK). Measurements were done in the same laboratory with the origin of the samples 
blinded to the operator. The intra- and inter-assay coefficients of variation were 1.7% 
and 3.7%, respectively. 
Mortality data 
Dates of death were obtained from the Spanish National Death Index (Ministry of 
Health and Social Services) for TSHA participants and from the death registries of 
regional Councils for AMI participants. Where necessary deaths were confirmed by 
follow-up telephone interviews with relatives of the deceased. Time to death was 
measured for up to 6 years from baseline, at which point the study was right-
censored. 
Other variables 
Sociodemographic, behavioural and health-related factors recorded at baseline are 
described in Appendix 1. 
Data analysis 
Details of the data analysis are described in Appendix 1.  
Results 
Participant characteristics 
A flow chart depicting the selection of participants from the TSHA and AMI cohorts 
enrolled in FRAILOMIC and their progression through to the current study is shown 
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in Figure S1 (see Appendix 3, available at Age and Ageing online). The 691 
participants in the study sample included 550 non-frail and 141 frail individuals. The 
baseline demographic, behavioural and health characteristics of these two groups 
are summarized in Table 1. Frail participants were older and had a lower level of 
education than their non-frail counterparts, with a larger proportion of them being 
females. Frail participants had a mildly reduced kidney function, higher BMI, higher 
rates of obesity and a higher dependence for basic ADLs. They also showed a 
higher prevalence of comorbidities, including diabetes, cardiovascular disease and 
stroke, but not of cancer or hypertension. In addition, there was a non-significant 
tendency of frail participants to have higher baseline levels of sRAGE compared with 
those that were non-frail. 
sRAGE levels and mortality 
During the six year follow-up 101 deaths were recorded, 51 occurring within the non-
frail group (9.3%) and 50 within the frail group (35.5%). The characteristics of frail 
and non-frail participants according to their survival status are summarized in Table 
S1 (see Appendix 3). Notably, in the frail group baseline sRAGE levels were 
significantly higher in individuals who had died compared to those who had survived 
(1563 [1015-2248] pg/mL vs 1184 [870-1657] pg/mL, P=0.006). In contrast, no 
difference in sRAGE was seen between non-survivors and survivors of the non-frail 
group (1262 [1056-1554] pg/mL vs 1186 [919-1551] pg/mL, P=0.19). Additional 
differences between survivors and non-survivors are described in Appendix 2, 
available at Age and Ageing online. 
The relationship between sRAGE and mortality was investigated by Cox proportional 
hazards regression analysis. The univariate analysis of the full analytical sample 
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demonstrated that sRAGE (entered as a natural logarithm-transformed continuous 
variable) was a significant predictor of mortality (HR=2.20, 95%CI 1.43-3.36, 
P<0.001). In addition, a significant interaction between sRAGE and frailty was 
observed (Table 2). Hence, we repeated the regression analysis after stratification 
by frailty status (see Table S2 in Appendix 3). In frail participants sRAGE remained a 
significant predictor of mortality (HR=2.69, 95%CI 1.53-4.76, P=0.001), but notably, 
not in those that were classified as non-frail (HR=1.51, 95%CI 0.81-2.82, P=0.196). 
Several other characteristics were also associated with mortality in the full sample 
(Table S2). These included age, gender, smoking history, total cholesterol, 
creatinine, eGFR, inability to perform basic ADLs, frailty and a diagnosis of diabetes, 
cardiovascular disease or stroke. Except for cholesterol and diabetes, these 
variables remained associated with mortality both in the non-frail and frail groups. 
To examine further the association between sRAGE and mortality, we compared four 
successive nested multivariate models adjusted for relevant sociodemographic, 
behavioural and health indicators (for details of model construction see Appendix 1). 
As shown in Table 2, a significant association between sRAGE and mortality 
persisted across all models, both for the whole sample and for the frail group, but 
was absent in the non-frail group. Furthermore, the interaction between sRAGE and 
frailty was also maintained. Concerning the frail group, adjusting for the cohort origin 
did not alter the relationship between sRAGE and mortality observed in the 
unadjusted analysis. Further adjustment for age and gender attenuated the 
association slightly. Finally, addition of health indicators showed that these had no 
influence. Altogether, the fully adjusted model indicates that frail individuals are 2.7-
fold more likely to die at any given time during the six year follow-up period per unit 
increment of ln-sRAGE (HR=2.72, 95%CI 1.48-4.99, P=0.001). Accordingly, a 
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secondary analysis where sRAGE levels were divided by subsample quartiles (see 
Table S3 in Appendix 3), showed that frail participants in the highest quartile of 
sRAGE had a 3.5-fold greater risk of death than those in the lowest quartile 
(HR=3.51, 95%CI 1.38-8.91, P=0.008). An alternative quartile-based analysis with 
sRAGE cut-offs set from the entire analytical sample is described in Appendix 2. 
Given that renal function is known to affect sRAGE levels [7], we also explored 
whether there was an interaction effect between eGFR and sRAGE on mortality. 
However, in this case the interaction term was found to be non-significant (data not 
shown). 
Figure 1 shows the Kaplan-Meier survival curves for non-frail and frail participants by 
subsample quartiles of sRAGE. In frail participants there was a significant difference 
in survival rates (P=0.002), with ~67% of those in the lowest quartile still being alive 
at the end of the follow-up, compared to ~36% of those in the highest quartile. 
Furthermore, the difference in survival became apparent after the first two years of 
follow-up. In contrast, survival rates of non-frail participants were similar across all 
quartiles of sRAGE (P=0.28). Comparable results were obtained when sRAGE cut-
offs were set from the full sample (data not shown). 
Performance of sRAGE in a mortality risk model 
Area under the ROC curve (AUC) analysis over different time horizons showed that 
for frail participants inclusion of sRAGE in the regression model consistently 
increased its predictive accuracy (see Figure S2 in Appendix 3). Accordingly, the 
average AUC increased from 0.841 (95%CI 0.838-0.845) without sRAGE to 0.870 
(95%CI 0.867-0.874) after sRAGE was included. In contrast, for non-frail individuals, 
inclusion of sRAGE showed no additional discriminatory value over that afforded by 
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using traditional indicators (AUC=0.825, 95%CI 0.822-0.829 without sRAGE 
compared to AUC=0.828, 95%CI 0.825-0.831 with sRAGE). 
Discussion 
In the present study, we found that among older adults diagnosed with frailty the risk 
of mortality over a six-year period increased significantly with increasing baseline 
serum sRAGE concentrations. On average, the hazards ratio of mortality in these 
individuals increased more than 2.5-fold with every unit increase in ln-sRAGE. This 
association was independent of age, gender, smoking history, cholesterol, renal 
function, ADLs, comorbidities (diabetes, cardiovascular disease, stroke and cancer) 
and the cohort origin of the participants. Importantly, we found that the frailty status 
influences the association between sRAGE and mortality, this relationship being 
significant only in frail individuals. Thus, our study suggests that sRAGE is an 
independent predictor of mortality in frail older adults.  
To our knowledge, the relationship between sRAGE and mortality in connection with 
frailty has not been previously explored. On the other hand, a number of clinical 
studies have examined the relationship between sRAGE and mortality outcomes in 
the absence or presence of disease, producing mixed results. Thus for example, 
high sRAGE levels predicted mortality in sepsis [15], cardiovascular disease [16], 
type I [17, 18] and type II diabetes [19], but not in patients with advanced chronic 
kidney disease [20-22], while low levels predicted mortality in people without 
cardiovascular disease at baseline [23] and in cancer [24]. Therefore, the 
relationship between sRAGE and mortality appears to be complex and influenced, at 
least in part, by the pathophysiological context. In this respect, it could be argued 
that our results merely reflected the high prevalence of diabetes and cardiovascular 
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disease in the frail group. However, the finding that this relationship was not 
attenuated after adjusting for those comorbidities, does not support this possibility. 
Reduced renal function may increase circulating sRAGE levels [7, 25, 26]. In our 
sample average eGFR values suggested that both frail and non-frail participants had 
a somewhat reduced kidney function; this is likely normal for their age. Yet, non-frail 
participants had on average a slightly higher eGFR than those that were frail, and 
this could explain in part why sRAGE was marginally elevated in the latter. 
Nevertheless, the association between sRAGE and mortality was independent of the 
eGFR, indicating that reduced kidney function was not an influencing factor.  
The biological mechanisms through which sRAGE might be related to mortality in 
frail individuals only have yet to be delineated. Non-survivors in that group did not 
seem to show a higher degree of frailty at baseline. In addition, it is unlikely that 
sRAGE affects survival directly. Instead, sRAGE may be a biomarker of chronic 
stress and inflammation. In making this distinction it should be noted that although 
sRAGE can play a protective role as an extracellular decoy of membrane-bound 
RAGE, thereby blocking intracellular signaling, its circulating levels may not always 
be sufficient to neutralize pro-inflammatory RAGE ligands [27]. Alternatively, raised 
sRAGE levels could simply reflect the overstimulation of cell surface RAGE by stress 
and damage-associated molecules, which would lead to the induction of further 
RAGE expression and subsequent increased shedding into the circulation [6]. Thus, 
stimulation of the RAGE pathway may be a sign of excessive cellular stress, which in 
frail people could over the long-term exacerbate their underlying vulnerability, 
leading to an increase in mortality. Conversely, non-frail people may be more 
resilient to the adverse causes of RAGE stimulation. 
11 
 
In our study adding sRAGE to conventional demographic, lifestyle and clinical 
parameters improved by 0.029 (~3%) the accuracy with which up to 6 years mortality 
could be predicted in frail subjects. Another study in adults from England and Wales 
aged 85 and older has shown that a combination of blood biological markers, which 
did not include sRAGE, improved the discriminative ability of a clinical deficit frailty 
index to predict mortality [28]. Thus, our results raise the possibility that adding 
sRAGE to other biological measures may further improve this estimation. 
The current findings could have important implications regarding the clinical 
management of frail older adults. In this respect, a clinically relevant threshold has 
so far not been established. Based on the present categorisation of sRAGE 
concentrations by quartiles, we tentatively suggest that a value of sRAGE above 
1800 pg/mL might be a relevant threshold that could be used for risk stratification. 
Nevertheless, further cohort studies will be required to either validate or modify this 
value. Similarly, interventional studies in frail people with low and high levels of 
sRAGE could ascertain the practical utility of this biomarker. 
The present study has important strengths, including that it has been performed with 
participants from well-characterised longitudinal cohorts, for whom large numbers of 
baseline sociodemographic and health indicators were available. Furthermore, a 
priori data homogenization within the FRAILOMIC framework and the determination 
of sRAGE in the same laboratory have enabled data pooling from separate cohorts, 
thus achieving a sufficiently large sample size to discover meaningful associations. 
Nonetheless, the study also has a number of limitations. Participants were mostly 
white Europeans, so the findings might not generalise to other populations, 
particularly given the fact that sRAGE is known to vary with race [7, 23]. In addition, 
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esRAGE was not measured in this study and although esRAGE and sRAGE are 
generally positively correlated [7], we cannot confirm if evaluating different forms of 
sRAGE will produce similar results. A final limitation of our study is its inability to 
establish if the observed relationship between sRAGE and mortality is part of a 
heightened inflammatory state involving RAGE activation, since no data on RAGE 
ligands was available. 
In summary, despite the above-mentioned limitations, our study adds to the growing 
literature relating biomarkers of inflammation to frailty [10, 29, 30], and might have 
implications for understanding the biological pathways which influence outcomes in 
this growing sub-population of older adults. We report for the first time that in older 
adults living with frailty (and only in that sub-group), increased levels of sRAGE are 
associated with a higher risk of death. Validation in additional cohorts and 
interventional studies are needed to establish the utility of this biomarker in the 
clinical management of frail older adults. 
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Sociodemographic and behavioural parameters 













Age in years, median [IQR] 75.0 [71.0-78.0] 74.0 [70.0-77.0] 79.0 [75.5-83.0] <0.001 
Male, % (n) 49.6 (343) 52.9 (291) 36.9 (52) 0.001 




















Smoking history, % (n) 32.9 (227) 32.9 (181) 32.6 (46) 0.949 
Laboratory and biomedical parameters 
sRAGE, median [IQR], pg/mL 1211 [923-1609] 1200 [923-1551] 1294 [916-1887] 0.094 
Total cholesterol, mean ± SD, mg/dL  199.3 ± 40.0 200.1 ± 39.6 195.9 ± 41.5 0.280 
Creatinine, median [IQR], mg/dL 0.9 [0.7-1.0] 0.9 [0.7-1.0] 0.9 [0.7-1.1] 0.160 
eGFR, median [IQR], mL/min/1.73m2 76.6 [61.5-87.8] 78.1 [63.4-88.6] 70.6 [53.6-83.6] <0.001 
BMI,  median [IQR], kg/m2 28.2 [25.5-31.2] 27.9 [25.4-30.8] 29.3 [25.8-32.9] 0.004 
Obesity, % (n) 34.9 (241) 32.4 (178) 44.7 (63) 0.007 
ADL, % dependent (n) 10.9 (75) 2.5 (14) 43.3 (61) <0.001 
Frailty, % (n) 20.4 (141) - - - 
Diabetes, % (n) 17.7 (122) 16.0 (88) 24.1 (34) 0.029 
Hypertension, % (n) 61.1 (422) 60.5 (333) 63.1 (89) 0.575 
Cardiovascular disease, % (n) 16.6 (115) 14.0 (77) 27.0 (38) <0.001 
Stroke, % (n) 5.5 (38) 4.0 (22) 11.3 (16) 0.001 
Cancer, % (n) 8.7 (60) 8.9 (49) 7.8 (11) 0.673 
Abbreviations: sRAGE, soluble receptor for advanced glycation-end products; eGFR, 
















* P value for the interaction between sRAGE and frailty 
Model 1: Multivariate model adjusted for cohort 
Model 2: Model 1 additionally adjusted for age and gender  
Model 3: Model 2 additionally adjusted for smoking history, total cholesterol, eGFR, ADL, diabetes, cardiovascular disease and stroke 
Model 4: Model 3 additionally adjusted for cancer 
 
 All (n=691)  Non-frail (n=550)  Frail (n=141)  
 HR 95% CI P  HR 95% CI P  HR 95% CI P 
P  for 
interaction* 
Unadjusted 2.20 1.43-3.36 <0.001  1.51 0.81-2.82 0.196  2.69 1.53-4.76 0.001 <0.001 
Model 1 2.25 1.46-3.45 <0.001  1.53 0.82-2.87 0.185  2.65 1.51-4.66 0.001 0.001 
Model 2 1.81 1.17-2.80 0.008  1.34 0.70-2.58 0.379  2.30 1.33-3.98 0.003 0.007 
Model 3 1.84 1.19-2.84 0.006  1.45 0.73-2.91 0.289  2.73 1.48-5.03 0.001 0.005 






Figure 1: Kaplan-Meier survival curves of non-frail and frail participants by quartiles 
of sRAGE. Cut-offs were set separately according to the distribution of sRAGE in 
each individual subsample.  
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Appendix 1: Supplementary Methods 
Study cohorts and selection of FRAILOMIC participants 
The Toledo Study of Healthy Ageing (TSHA) is a prospective cohort study initiated in 
2006 aimed at studying the determinants and consequences of frailty in community-
dwelling older adults living in the city of Toledo and neighbouring towns, Spain [1]. 
The Approche Multidisciplinaire Intégrée (AMI) is a population-based prospective 
cohort started in 2007 to study health and ageing in elderly farmers living in rural 
South West France [2]. The complete methodologies for recruitment and 
investigations of participants from the two cohorts have been reported elsewhere [1-
3]. In both cohorts, once the participants gave written informed consent, biological 
samples and a wide range of sociodemographic, behavioural and health-related data 
were collected between 2006 and 2009 by trained psychologists and/or nurses 
during home visits. Individuals were considered for inclusion in FRAILOMIC if a 
stored sample of plasma, serum and/or urine was available for biomarker evaluation 
and if the frailty status could be determined from case report forms using the frailty 
criteria proposed by Fried et al. [4] (see below). A total of 1398 participants from 
TSHA and 695 from AMI fulfilled the aforementioned selection criteria. To ensure 
adequate numbers of participants for statistical analysis, enrolment to FRAILOMIC 
was carried out to achieve an approximate ratio 1 frail to 3 non-frail subjects and a 
similar cardiovascular risk profile in both groups. This resulted in 474 subjects from 
TSHA (109 frail and 365 non-frail) and 320 subjects from AMI (80 frail and 240 non-





Measurement of frailty 
The five frailty parameters were defined as follows: 1) Slow walking speed was 
defined as the worst quintile in a 3-meter walking speed test, adjusted for gender 
and height. 2) Weakness was defined as the lowest quintile of grip strength 
measured with a Jamar hand dynamometer, after adjustment for gender and BMI (in 
kg/m2) in TSHA [5] or as having difficulty rising from a chair without using armrests in 
AMI [6]. 3) Weight loss, was defined as the unintentional loss of at least 4.5 kg in the 
preceding year in TSHA or ≥3 kg in the previous 3 months in AMI. 4) Self-reported 
exhaustion was evaluated in both cohorts based on a positive response to any of the 
following questions from the Center for Epidemiologic Studies Depression Scale [7]: 
“I felt that anything I did was a big effort” or “I felt that I could not keep on doing 
things” “at least 3-4 days a week”. 5) Low physical activity was defined as the lowest 
quintile for each gender of the Physical Activity Scale for the Elderly [8] in the case of 
TSHA, and as <1 hour of exercise/week or <3.5 hours of leisure activities/week in 
AMI. Individuals from the two cohorts whose case report forms had missing 
information on one or two parameters, but for whom their frailty status could still be 
assigned based on the remaining recorded parameters, were also included in 
FRAILOMIC. 
Other variables 
Sociodemographic and behavioural information recorded at baseline included age, 
gender, level of education and smoking history. Participants were also asked to 
report whether they had previously suffered from any of the following physician-
diagnosed diseases: hypertension, diabetes, cardiovascular disease (ischemic heart 
disease or heart failure), stroke or cancer. Body Mass Index (BMI) was calculated as 
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weight in kilograms divided by height in meters squared. Limitations in activities of 
daily living (ADLs) were measured with the use of the Katz ADL Scale [9]. Obesity 
was defined according to World Health Organization guidelines. Cholesterol and 
creatinine were measured from fasting blood samples by routine enzymatic methods. 
The estimated glomerular filtration rate (eGFR) was calculated using the CKD-EPI 
creatinine equation [10].  
Analytical sample 
Of the original participants included in the FRAILOMIC database, 48 from TSHA and 
2 from AMI who did not have enough stored serum to measure sRAGE were 
excluded from the present study. Similarly, 3 participants from TSHA and 30 from 
AMI who did not have complete frailty data were also excluded. This left a combined 
TSHA-AMI sample pool of 711 participants. Of these, we further excluded 16 
participants for missing covariates at baseline. We also excluded 4 additional 
participants for giving extremely high values of sRAGE (over 4 standard deviations 
above the mean), thus leaving a total of 691 participants in the analytical sample 
(See Figure S1). 
Data analysis 
Data obtained from the case report forms were harmonised, thus allowing for data 
pooling. For comparison of sociodemographic characteristics and health indicators 
continuous variables are reported as means ± SD for normally distributed data or as 
medians with IQR for skewed data. Categorical variables are presented as 
percentages. Differences in characteristics between frail and non-frail groups or 
between survivors and non-survivors were compared by χ2 test or Fisher’s exact test 
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for categorical variables, and by Student’s t test or Mann-Whitney test for continuous 
variables, as appropriate.  
Unadjusted and adjusted Cox proportional hazards regression models examining the 
associations between sRAGE and mortality were performed with SSPS v.23 for 
Windows (SSPS Inc., Chicago, Illinois). Given the skewed distribution of sRAGE, for 
its evaluation as a continuous variable it was natural log-transformed before further 
analysis. Multivariate models included those variables identified by univariate 
analysis as conferring a statistically significant risk of death (P<0.05) in the full 
analytical sample. In addition, models were adjusted for cohort origin and history of 
cancer, as these were deemed covariates of potential important demographic or 
clinical influence, respectively. Accordingly, four successive nested models were 
constructed: Model 1 was adjusted for cohort origin; model 2 included the variables 
of model 1 plus those basic demographic characteristics which were identified as 
statistically significant in the univariate analysis (age and gender); model 3 included 
all the variables in model 2 plus health and lifestyle covariates which were identified 
as significant in the univariate analysis (smoking history, total cholesterol, eGFR, 
ADL, diabetes, cardiovascular disease and stroke); and model 4 included the 
variables of model 3 plus cancer. All models were also examined for interactions by 
frailty status and by eGFR. Analyses were initially conducted in the full analytical 
sample and then repeated for the frail and non-frail groups, given the significant 
interaction observed between sRAGE and frailty. Division between robust and pre-
frail participants, in accordance with the original Fried’s classification [4], was 
deemed unsuitable in this instance due to the relative low number of events 
registered in each of these categories (16 and 35 deaths, respectively), vis-à-vis the 
number of covariates included in the regression models [11]. Thus, in order to control 
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adequately for confounders, robust and non-frail participants were pooled into a 
single group. 
Kaplan-Meier survival curves were plotted with sRAGE categorised by subsample 
quartiles (frail or non-frail) or by cut-offs set from quartiles of the entire analytical 
sample. Survival curves were compared by the Mantel-Cox log-rank test using 
GraphPad Prism (v.5.01). The time interval was calculated as the period between 
baseline blood sampling and the date of death or being censored after 6 years. 
The area under the ROC curve (AUC) was computed for every week over a time 
interval from two to six years of follow-up using a logistic regression model, which 
included or excluded sRAGE; this analysis was performed with the Statistical 
package R v2.15.2 for Windows (Vienna, Austria). The integrated AUC was plotted 
using these values against time, with Graph Pad Prism (v.5.01). 
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Appendix 2: Supplementary Results 
Characteristics of participants according to their survival status 
Table S1 shows the baseline characteristics of non-frail and frail participants by 
survival status. In both the frail and the non-frail groups, participants who had died 
were older than those who had survived, with a higher percentage of them being 
male. Additionally, non-survivors were more likely to have limitations in basic ADLs 
and a lower eGFR. On the other hand, some phenotypic differences were specific to 
either the frail or the non-frail group. Non-frail participants who died were more likely 
to have lower cholesterol levels, a history of smoking, and higher rates of 
cardiovascular disease and stroke. In contrast, in the frail group, those who died had 
higher rates of diabetes, but no difference was seen in the prevalence of each frailty 
criterion. In a further search for quantitative differences in the degree of frailty 
between survivors and non-survivors of this group, baseline gait speeds were 
compared. In frail men the mean (SD) gait speed was 0.44 ± 0.19 m/sec for 
survivors vs. 0.41 ± 0.29 m/sec for non-survivors, P=0.31, whereas in frail women 
these values were 0.35 ± 0.16 m/sec vs. 0.29 ± 0.15 m/sec, respectively, P=0.09. 
Taken together, these results suggest that within the frail group non-survivors did not 
seem to have a more pronounced degree of frailty.  
Cox regression analysis according to sRAGE quartiles of the analytical sample 
Table S4 shows a quartile-based comparison of the relationship between sRAGE 
and mortality with sRAGE categorised according to cut-offs set from the entire 
analytical sample. Consistent with the results obtained using subsample quartiles, 
this alternative analysis showed that frail participants who fell above the highest cut-
off level of sRAGE had a 2.6-fold greater risk of death than those that fell below the 
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lowest cut-off (HR=2.62, 95%CI 1.07-6.42, P=0.036). In contrast, no significant 
increase in the risk of death was observed using the same sRAGE cut-offs in the 
non-frail group (HR=1.37, 95%CI 0.56-3.35, P=0.497).  
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Table S1: Baseline characteristics of study participants by survival status 
 
 


































































































Smoking history, % 30.7 45.5 0.003  31.3 49.0 0.010  27.5 42.0 0.078 
sRAGE, median [IQR], pg/mL 
1185 
[916-1559] 










1563      
[1015-2248] 
0.006 
Total cholesterol, mean ± SD, 
mg/dL 
201.2 ± 39.6 188.2 ± 40.8 0.004 
 
202.0 ± 39.3 181.7 ± 39.0 0.001 
 
196.5 ± 41.5 194.9 ± 41.8 0.824 
Creatinine, median [IQR], 
mg/dL 
0.9 [0.7-1.0] 1.0 [0.8-1.3] <0.001 
 
0.8 [0.7-1.0] 0.9 [0.8-1.2] 0.002 
 
0.9 [0.7-1.0] 1.0 [0.8-1.3] 0.014 



















Table S1 continued            
















Obesity, % 34.9 34.7 0.959  32.9 27.5 0.431  46.1 42.0 0.635 
ADL, % dependant 7.3 31.7 <0.001  2.0 7.8 0.012  44.0 56.0 0.024 
Frailty, % 15.4 49.5 <0.001  - - -  - - - 
Slowness, % 23.2 57.4 <0.001  11.4 23.5 0.013  87.9 92.0 0.451 
Weakness, % 22.4 49.5 <0.001  13.2 21.6 0.102  72.5 78.0 0.476 
Weight loss, % 12.7 18.8 0.098  9.4 7.8 0.712  30.8 30.0 0.924 
Exhaustion, % 13.7 32.7 <0.001  6.6 11.8 0.172  52.7 54.0 0.887 
Low physical activity, % 21.4 53.5 <0.001  11.2 29.4 <0.001  76.9 78.0 0.884 
Diabetes, % 15.8 28.7 0.002  15.2 23.5 0.124  18.7 34.0 0.042 
Hypertension, % 60.8 62.4 0.771  59.9 66.7 0.348  65.9 58.0 0.350 
Cardiovascular disease, % 13.7 33.7 <0.001  12.2 31.4 <0.001  22.0 36.0 0.073 
Stroke, % 4.1 13.9 <0.001  2.8 15.7 <0.001  11.0 12.0 0.856 





Table S2: Univariate analysis for potential contributing factors of mortality 
 
 All (n=691)  Non-frail (n=550)  Frail (n=141) 
Variable HR 95% CI P  HR 95% CI P  HR 95% CI P 
Cohort 0.77 0.50-1.18 0.231  0.85 0.47-1.54 0.591  0.58 0.32-1.08 0.084 
Age 1.16 1.12-1.19 <0.001  1.16 1.11-1.22 <0.001  1.10 1.05-1.16 <0.001 
Male gender 1.88 1.25-2.80 0.002  2.65 1.43-4.90 0.002  2.22 1.28-3.88 0.005 
Education 0.71 0.35-1.47 0.361  0.76 0.30-1.92 0.564  1.09 0.34-3.52 0.881 
Smoking history 1.84 1.24-2.72 0.002  2.04 1.18-3.53 0.011  1.83 1.04-3.22 0.035 
Ln sRAGE 2.20 1.43-3.36 <0.001  1.51 0.81-2.82 0.196  2.69 1.53-4.76 0.001 
Total cholesterol 0.99 0.99-1.00 0.006  0.99 0.98-0.99 0.001  1.00 0.99-1.01 0.746 
Creatinine 2.84 2.20-3.67 <0.001  2.80 1.95-4.02 <0.001  2.93 1.90-4.53 <0.001 
eGFR 0.97 0.96-0.98 <0.001  0.97 0.95-0.98 <0.001  0.98 0.96-0.99 0.003 
BMI 0.97 0.93-1.02 0.216  0.96 0.90-1.03 0.234  0.95 0.90-1.00 0.064 
Obesity 0.93 0.62-1.41 0.740  0.75 0.41-1.39 0.364  0.81 0.46-1.43 0.471 
ADL 4.30 2.82-6.53 <0.001  3.59 1.29-9.97 0.014  1.81 1.04-3.17 0.037 
Frailty 4.19 2.84-6.19 <0.001         
Diabetes 1.98 1.28-3.04 0.002  1.61 0.84-3.08 0.148  2.11 1.17-3.79 0.013 
Hypertension 1.17 0.78-1.76 0.439  1.41 0.79-2.53 0.244  0.90 0.51-1.57 0.702 
Cardiovascular disease 3.07 2.03-4.64 <0.001  3.23 1.78-5.84 <0.001  1.93 1.08-3.44 0.026 
Stroke 3.02 1.72-5.32 <0.001  4.99 2.34-10.61 <0.001  1.06 0.45-2.49 0.893 
Cancer 1.41 0.75-2.64 0.281  1.46 0.62-3.43 0.382  1.45 0.57-3.65 0.433 
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Table S3: Multivariate Cox proportional hazard models of the relationship between sRAGE and mortality in frail participants 
according to sRAGE quartiles  
 
 
Model 1: Multivariate model adjusted for cohort 
Model 2: Model 1 additionally adjusted for age and gender 
Model 3: Model 2 additionally adjusted for smoking history, total cholesterol, eGFR, ADL, diabetes, cardiovascular disease and stroke 
Model 4: Model 3 additionally adjusted for cancer 
* Cut-offs based on quartiles of the frail group 
 
  
 Model 1  Model 2  Model 3  Model 4 
 HR 95% CI P  HR 95% CI P  HR 95% CI P  HR 95% CI P 
sRAGE quartiles* 
Q1, <915.7 pg/mL 
Q2, 915.7-1293.9 pg/mL 
Q3,1294-1887 pg/mL 

































































Table S4: Comparison of the relationship between sRAGE and mortality in frail and non-frail participants based on analytical 
sample quartiles 
 
The multivariate model was adjusted for cohort, age and gender, smoking history, total cholesterol, eGFR, ADL, diabetes, cardiovascular 
disease, stroke and cancer (model 4 in Table S3) 
* Cut-offs based on quartiles of the entire analytical sample 
 
 All (n=691)  Non-frail (n=550)  Frail (n=141) 
 n HR 95% CI P  n HR 95% CI P  n HR 95% CI P 
sRAGE quartiles* 
Q1, <923.4 pg/mL 
Q2, 923.4-1211.1 pg/mL 
Q3,1211.2-1608.7 pg/mL 
Q4, >1608.7 pg/mL 




































































Figure S1: Flow chart of the study sample selection. Details of the selection of 













































Figure S2: Integrated AUCs for different time horizons. Values were calculated for 
hazards models that included or excluded sRAGE, as indicated.  
